Boussard & Gavaudan Investment Management LLP Sells 80,500 Shares of Catalent, Inc. (NYSE:CTLT)

Boussard & Gavaudan Investment Management LLP lessened its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 21.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 302,336 shares of the company's stock after selling 80,500 shares during the quarter. Catalent comprises about 1.7% of Boussard & Gavaudan Investment Management LLP's investment portfolio, making the stock its 20th biggest position. Boussard & Gavaudan Investment Management LLP owned about 0.17% of Catalent worth $18,261,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brooklyn Investment Group acquired a new stake in shares of Catalent in the third quarter worth $31,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalent during the second quarter valued at about $42,000. Sentry Investment Management LLC acquired a new position in shares of Catalent during the third quarter valued at about $53,000. Longfellow Investment Management Co. LLC grew its position in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock worth $55,000 after buying an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock valued at $58,000 after acquiring an additional 212 shares during the period.

Catalent Price Performance

CTLT stock traded up $0.25 during trading on Thursday, hitting $61.00. 1,498,729 shares of the stock traded hands, compared to its average volume of 2,036,391. The stock has a market cap of $11.07 billion, a price-to-earnings ratio of -26.99, a P/E/G ratio of 2.44 and a beta of 1.16. Catalent, Inc. has a one year low of $36.74 and a one year high of $61.50. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The company has a 50 day simple moving average of $59.86 and a 200 day simple moving average of $58.41.

Catalent (NYSE:CTLT - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the firm earned ($0.10) earnings per share. The firm's revenue was up 4.2% compared to the same quarter last year. Equities analysts expect that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CTLT has been the subject of a number of research reports. William Blair reiterated a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. Baird R W downgraded shares of Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Robert W. Baird reaffirmed a "neutral" rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Finally, StockNews.com lowered shares of Catalent from a "hold" rating to a "sell" rating in a research report on Friday, November 22nd. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $63.40.

Insider Activity

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares of the company's stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,114 shares of company stock worth $305,931. 0.31% of the stock is owned by corporate insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.